Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5421 - Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Murat Araz

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

M. Araz1, M. Karaağaç2, L. Korkmaz3, L. Koral4, F. İnci5, I. Beypinar6, M. Uysal1, M. Artac3

Author affiliations

  • 1 Medical Oncology, Afyon Kocatepe University School of Medicine, 03200 - Afyonkarahisar/TR
  • 2 Medical Oncology, Necmettin Erbakan University Faculty of Medicine, Konya/TR
  • 3 Medical Oncology, Necmettin Erbakan University, Konya/TR
  • 4 Medical Oncology, Çanakkale Onsekiz Mart University, 17100 - Çanakkale/TR
  • 5 Medical Oncology, Karabük State Hospital, Karabük/TR
  • 6 Medical Oncology, Afyon Kocatepe University Department of Medical Oncology, 03218 - Afyonkarahisar/TR
More

Resources

Abstract 5421

Background

In the literature, there have been only two head to head trials investigating first and second generation 5HT3 receptor antagonists in triplet antiemetic regimens in cancer patients receiving high emetogenic chemotherapy (HEC). In these two Japanese studies, granisetron(G) was compared with 0.75 mg palonosetron(P). However, P is approved as 0.25 mg in Turkey and most other countries. Therefore, we aimed to investigate the efficacy of 0.25 mg of P and G in triplet antiemetic regimen for HEC.

Methods

This study was carried out between April 2017 and December 2017 at four different cancer center in Turkey. Patients with nonmetastatic breast cancer who received HEC (doxorubicin or epirubicin plus cyclophosphamide (AC/EC)) were enrolled in this study. The prophylactic triplet antiemetic regimens were used during the first cycle of HEC as intravenous dexamethasone and P (0.25 mg) or G (3mg) as well as oral aprepitant(125 mg on day 1 and 80 mg/day on days 2–3). The choice of P or G was left to the doctor's preference. The primary endpoint was complete response rate (CCR) in acute and delayed chemotherapy-induced nausea and vomiting (CINV). MASCC Antiemesis Tool was used to assess the CINV.

Results

A total of 118 female patients were included in the study. None of them had alcohol consumption story. The mean age of the patients was 51 years. Patients received AC (83%), EC (3%), and dose-dense AC (14%) as adjuvant (88%) or neoadjuvant (12%). The majority of patients received P (59%) containing antiemetic treatment. The dexamethasone dose used in the majority was 8 mg (%80). The CCRs on vomiting were high in two arms and not statistically different with P and G (acute 87% vs. 96%, p = 0.089; delayed 90% vs. 92%, p = 0.508), respectively. Nevertheless, the CCRs of either acute or delayed nausea were lower than compared with vomiting (acute 50% vs. 53%, p = 0.475; delayed 41% vs 31%, p = 0.186), respectively.

Conclusions

To best our knowledge, this is the first study that compared 0.25 mg P and G in triplet antiemetic regimens in cancer patients receiving HEC. There were no differences between P and G, in terms of CCRs of acute and delayed CINV.

Clinical trial identification

Legal entity responsible for the study

Murat Araz.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.